In a recent statement, the US Food and Drug Administration (FDA) cautioned the public about the presence of counterfeit versions of the popular type 2 diabetes drug Ozempic in the US drug supply chain. The FDA reported that it has seized "thousands of units" of the fake medications and is urging suppliers, pharmacies, and patients to exercise caution.

The agency disclosed that, to date, there have been five reported cases of individuals falling ill in connection with the counterfeit products. However, none of the cases have resulted in serious health complications, as confirmed by the FDA.

In light of the discovery, the FDA is calling on pharmacies, healthcare systems, wholesalers, and patients to double-check their semaglutide products to ensure their authenticity. Specifically, the agency advised against using one-milligram injectable Ozempic products with the lot number NAR0074 and serial number 430834149057 on the box.

The FDA joined forces with the drug manufacturer Novo Nordisk to conduct testing on the counterfeit medications in order to determine any potential dangers and identify the substances involved. It was revealed that not only the medication itself but also the pen label, carton, information for patients and healthcare professionals, and needles found with the injectors are counterfeit. Due to the uncertainty surrounding the sterility of these fake needles, their use could potentially lead to infections.

As a precautionary measure, the FDA reminded patients to obtain their medication exclusively from state-licensed pharmacies possessing a valid prescription.

The surge in popularity of Ozempic, particularly among celebrities who used it for weight loss purposes, has created a shortage in supply. Consequently, reports have emerged of individuals attempting to sell counterfeit versions, both in salons and through social media channels. In response, the FDA has issued warning letters to online sellers, demanding they cease the sale of knockoff products. Novo Nordisk has even taken legal action against medical spas, clinics, and weight loss clinics to prevent the sale of fake versions.

The FDA is actively collaborating with other federal agencies and Novo Nordisk to locate and remove additional counterfeit semaglutide injectable products from circulation.

Concerned consumers are encouraged to contact Novo Nordisk at 1-800-727-6500 with any inquiries or to report the presence of counterfeit products. Individuals may also inform their local FDA consumer complaint coordinator or report the counterfeit products directly on the FDA's website.

CORRECTION: An update has been issued to accurately reflect the quantity of counterfeit Ozempic that has been seized.

These counterfeit drugs have surfaced amidst the soaring demand for diabetes medication, prompting the FDA to issue a warning to the public.